CRISPR Therapeutics Corp (CRSP): קונצנזוס שווי הוגן

This price chart for CRISPR Therapeutics AG (CRSP) reflects the dynamics of a company developing innovative treatments through genome editing. The business relies on the exclusivity of the CRISPR/Cas9 system, which enables the elimination of hereditary defects amid inelastic demand, currently priced in at 83.10. However, long-term side effects and challenges regarding insurance reimbursement are creating pressure. Stability is supported by a solid liquidity reserve and the optimization of supply chains.

CRISPR Therapeutics AG (CRSP) leadership in gene editing and the success of Casgevy make the stock price dependent on expectations for future R&D breakthroughs. This indicator aggregates average expert price targets, filtering out random extremes to identify the fair market value. Comparing the current price with this value allows for the determination of the asset's degree of undervaluation. The trend of the analysts' consensus price forecast confirms the fundamental resilience of the business.